BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9722872)

  • 1. Polymerization of human prion peptide HuPrP 106-126 to amyloid in nucleic acid solution.
    Nandi PK
    Arch Virol; 1998; 143(7):1251-63. PubMed ID: 9722872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymerization of murine recombinant prion protein in nucleic acid solution.
    Nandi PK; Leclerc E
    Arch Virol; 1999; 144(9):1751-63. PubMed ID: 10542024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid.
    Nandi PK; Leclerc E; Nicole JC; Takahashi M
    J Mol Biol; 2002 Sep; 322(1):153-61. PubMed ID: 12215421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hetero-oligomeric Amyloid Assembly and Mechanism: Prion Fragment PrP(106-126) Catalyzes the Islet Amyloid Polypeptide β-Hairpin.
    Ilitchev AI; Giammona MJ; Olivas C; Claud SL; Lazar Cantrell KL; Wu C; Buratto SK; Bowers MT
    J Am Chem Soc; 2018 Aug; 140(30):9685-9695. PubMed ID: 29989407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlling {beta}-amyloid oligomerization by the use of naphthalene sulfonates: trapping low molecular weight oligomeric species.
    Ferrão-Gonzales AD; Robbs BK; Moreau VH; Ferreira A; Juliano L; Valente AP; Almeida FC; Silva JL; Foguel D
    J Biol Chem; 2005 Oct; 280(41):34747-54. PubMed ID: 16041062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of prion peptide HuPrP106-126 with nucleic acid.
    Nandi PK
    Arch Virol; 1997; 142(12):2537-45. PubMed ID: 9672613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osmolyte trimethylamine N-oxide converts recombinant alpha-helical prion protein to its soluble beta-structured form at high temperature.
    Nandi PK; Bera A; Sizaret PY
    J Mol Biol; 2006 Sep; 362(4):810-20. PubMed ID: 16949096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of prion peptide structure and aggregation in toxicity and membrane binding.
    Rymer DL; Good TA
    J Neurochem; 2000 Dec; 75(6):2536-45. PubMed ID: 11080207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism at residue 129 modulates the conformational conversion of the D178N variant of human prion protein 90-231.
    Apetri AC; Vanik DL; Surewicz WK
    Biochemistry; 2005 Dec; 44(48):15880-8. PubMed ID: 16313190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
    Baskakov IV; Bocharova OV
    Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological polyamines inhibit nucleic-acid-induced polymerisation of prion protein.
    Bera A; Nandi PK
    Arch Virol; 2007; 152(4):655-68. PubMed ID: 17219019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid fibrils of human prion protein are spun and woven from morphologically disordered aggregates.
    Almstedt K; Nyström S; Nilsson KP; Hammarström P
    Prion; 2009; 3(4):224-35. PubMed ID: 19923901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conformational dynamics of a hydrophobic prion fragment (113-127) in different pH and osmolyte solutions.
    Inayathullah M; Rajadas J
    Neuropeptides; 2016 Jun; 57():9-14. PubMed ID: 26919915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
    Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
    Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High pressure induces scrapie-like prion protein misfolding and amyloid fibril formation.
    Torrent J; Alvarez-Martinez MT; Harricane MC; Heitz F; Liautard JP; Balny C; Lange R
    Biochemistry; 2004 Jun; 43(22):7162-70. PubMed ID: 15170353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gold complexes inhibit the aggregation of prion neuropeptides.
    Wang X; He L; Zhao C; Du W; Lin J
    J Biol Inorg Chem; 2013 Oct; 18(7):767-78. PubMed ID: 23982344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic amyloidogenicity of mammalian prion proteins from species susceptible and resistant to prions.
    Nyström S; Hammarström P
    Sci Rep; 2015 May; 5():10101. PubMed ID: 25960067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Membrane interactions and conformational preferences of human and avian prion N-terminal tandem repeats: the role of copper(II) ions, pH, and membrane mimicking environments.
    Di Natale G; Pappalardo G; Milardi D; Sciacca MF; Attanasio F; La Mendola D; Rizzarelli E
    J Phys Chem B; 2010 Nov; 114(43):13830-8. PubMed ID: 20936829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical region for amyloid fibril formation of mouse prion protein: unusual amyloidogenic properties of the helix 2 peptide.
    Yamaguchi K; Matsumoto T; Kuwata K
    Biochemistry; 2008 Dec; 47(50):13242-51. PubMed ID: 19053276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of the anti-prionic activity of newly synthesized congo red derivatives.
    Poli G; Ponti W; Carcassola G; Ceciliani F; Colombo L; Dall'Ara P; Gervasoni M; Giannino ML; Martino PA; Pollera C; Villa S; Salmona M
    Arzneimittelforschung; 2003; 53(12):875-88. PubMed ID: 14750496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.